portfolio

Phagenesis

Phagenesis is a neurostimulation device company that has developed the first clinically proven treatment for dysphagia (inability to swallow safely) following a stroke. Dysphagia occurs in about half stroke patients, and leads to poor nutrition that may require tube-feeding with associated higher risk of pneumonia and early death.

Phagenesis Closes €7 Million Series B Financing Round

2011-10-04

Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.

Read the full article...

Daniel Green, Phagenesis:
"Inventages brings talent, imagination and rigor to the process of identifying suitable investments."

www.phagenesis.com

Back to portfolio ...

Yan Hervy, Velle Russia:
"Over the last year of cooperation, Inventages - through the very high caliber of its associates - has been able to challenge positively Velle Russia business from marketing vision to operational " More...